Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Clinical trial NCT06813911 · RECRUITING

Trial details

NCT number: NCT06813911
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Atherosclerotic Cardiovascular Disease (ASCVD)

Start date: 2025-04-30
Primary completion: 2028-02-03
Enrollment: 340

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.